Majoron-driven leptogenesis in gauged U ( 1 ) L μ − L τ model
Physical Review D · 12.11.2024 · 110 (10)
DOI: 10.1103/physrevd.110.103510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical Review D, online erschienen am 12.11.2024. Verfasst von Juntaro Wada. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
We propose a novel leptogenesis scenario in the gauged U ( 1 ) L μ − L τ model. Achieving successful leptogenesis in the U ( 1 ) L μ − L τ symmetric phase is challenging due to the absence of a C P phase, caused by restriction from the gauge symmetry. To overcome this issue, we introduce an additional global symmetry, U ( 1 ) B − L , and a scalar field Φ responsible for breaking this symmetry. Through the kinetic misalignment mechanism, the Majoron field associated with U ( 1 ) B − L symmetry breaking has a kinetic motion in the early Universe. Subsequently, time-dependent Majoron field background induces the background C P phase dynamically, leading to successful leptogenesis in the U ( 1 ) L μ − L τ symmetric phase. Furthermore, Majoron itself serves as a dark matter candidate in this scenario. As one of the phenomenological applications, we consider the model that can also explain the muon g − 2 anomaly. Published by the American Physical Society 2024
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Wada, J. (2024). Majoron-driven leptogenesis in gauged U ( 1 ) L μ − L τ model. Physical Review D, 110(10). https://doi.org/10.1103/physrevd.110.103510
Vancouver
Wada J. Majoron-driven leptogenesis in gauged U ( 1 ) L μ − L τ model. Physical Review D. 2024;110(10). doi:10.1103/physrevd.110.103510
BibTeX
@article{Wada2024,
author = {Wada, Juntaro},
title = {Majoron-driven leptogenesis in gauged U ( 1 ) L μ − L τ model},
journal = {Physical Review D},
year = {2024},
volume = {110},
number = {10},
doi = {10.1103/physrevd.110.103510}
}
EUVIMED